Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

11

Revenue 2014

AbbVie

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of AbbVie's 2013 sales performance.

Fresenius Kabi buys Akorn and Merck's biosimilar businesses

Fresenius Kabi buys Akorn and Merck's biosimilar businesses

Fresenius is paying 170m upfront for the portfolio - headed by a copy of AbbVie's $16bn blockbuster Humira (adalimumab) that has reached the phase III trial stage in chronic plaque psoriasis -

CHMP backs two rare disease therapies at April meeting

CHMP backs two rare disease therapies at April meeting Prior to the FDA rejection analysts were predicting big things for Sanofi and Regeneron's drug, particularly after it outperformed AbbVie's $14bn blockbuster Humira (adalimumab) in a head-to-head

AbbVie's PARP inhibitor veliparib fails to deliver

AbbVie's PARP inhibitor veliparib fails to deliver AbbVie's PARP inhibitor veliparib fails to deliver. Phase III trials show no increase in clinical benefit. ... AbbVie's hopes of launching a fourth PARP inhibitor onto the market have been dashed by two failed phase III trials for its veliparib candidate.

FDA turns down Lilly and Incyte JAK inhibitor after delay

FDA turns down Lilly and Incyte JAK inhibitor after delay Now it risks being caught up by other companies developing JAK inhibitors for arthritis, notably Gilead Sciences with filgotinib and AbbVie with ABT-494. ... Safety concerns have meant Xeljanz is typically reserved as a later-line therapy after

AbbVie and J&J file first non-cancer use for Imbruvica with FDA

AbbVie and J&J file first non-cancer use for Imbruvica with FDA AbbVie and J&J file first non-cancer use for Imbruvica with FDA. ... Seeks FDA approval to treat GVHD patients. Johnson &Johnson and AbbVie have successfully added multiple new indications to blood cancer blockbuster Imbruvica, and are now pitching for

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

How to find pharma content that inspires your audience
Getting your customers’ attention begins with presenting pharma content that speaks to their needs and wants effectively....
Bowel Cancer Awareness Month
Synergy Vision are supporting Bowel Cancer Awareness Month. Bowel cancer is one of most common cancers diagnosed in the UK, but with early diagnosis and treatment, most cases can be...
Anthill_icon_Green_18_Dialogue.png
The right way to capture customer data
Digital communication should be a two-way process with information flowing backwards and forwards between you and healthcare professionals. That digital technology enables HCPs to give feedback is a big part...

Infographics